INNOVATION PARK TICINO | SITE OF PARK ZURICH
|Date:||April 25, 2023|
|Time:||13:30 – 14:15|
Microphysiological systems and advanced 3D in vitro models as tools for innovating preclinical drug discovery
Drug development is known to be time consuming and very expensive. Pre-clinical studies are executed on animals to explore toxicity and pharmacology but often the responses are not accurate and do not perfectly reflect human physiology. The 3D in-vitro model is an innovating approach to accelerate drug development to predict toxicity and pharmacology using human cells. The panel will give an overview about the project and possible future applications.
Dr. Giorgio Calderari, Vice Chairman, Helsinn Group
Dr. Luca Bolzani, President, Fondazione Agire
Prof. Matteo Moretti, Regenerative Medicine Technologies Lab, Laboratories for Tranlational Research (EOC) & Faculty of Biomedical Sciences, Euler Institute, USI
Dr. Reto Naef, Founder and chairman of the board of directors, Topadur Pharma AG
Dr. Gionata Frasca, Co-Founder and Managing Director, CMC Pharmatech Sagl
Innovation Park Ticino, developed by Fondazione Agire under a mandate from the Ticino State Council, is enrolled under the law for regional economic development and formally ratified by the Ticino Parliament. With its association with Zurich, the Park builds on existing economic and scientific collaborations, and plans to create further synergies.